UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Entrada has several opportunities to strengthen its human evidence before March 2027. The central question is whether higher exposure and a second Duchenne program can resolve the uncertainties left by the first patient cohort, while a Vertex-partnered DM1 readout offers another test of the platform.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
First clinical evidence for ENTR-601-45 at 5 mg/kg. Safety, exposure and pharmacodynamic results matter more than the headline adjective. Source
Another major checkpoint: Q1 2027
ELEVATE-44-201: higher-dose cohort 2. A major clinical inflection point, rather than a single FDA decision: can 12 mg/kg improve useful exposure and biological activity without compromising safety? Source
The constructive case starts with a testable proposition: disappointing exposure in the first DMD cohort is a dose-selection problem that can be corrected while retaining an acceptable safety margin. If ENTR-601-44 produces a clearer dose-response at 12 mg/kg, and ENTR-601-45 generates a coherent first patient signal, the market could place greater value on the delivery approach rather than treating each asset as an isolated experiment. Longer follow-up would be especially useful if biological activity aligns with a durable functional pattern.
Vertex provides another route to validation and an economic interest in DM1 without Entrada funding the entire global program. Positive VX-670 evidence could strengthen confidence in the technology and future partnering discussions. The partnership demonstrates external commitment, although it does not prove the medicine works. Original Vertex agreement · Vertex clinical update
At a small capitalization, a meaningful reduction in scientific uncertainty can matter disproportionately. Cash gives the company time to obtain data, and stronger evidence could improve future financing terms. This is a case for potentially substantial repricing after better evidence, not a claim that a low share price, cash balance or prominent shareholder guarantees upside.
The adverse case is that increasing dose raises toxicity or complexity faster than it improves useful muscle delivery. A small, variable dystrophin response and a post hoc functional observation may fail to reproduce. Repeated announcements can then create the appearance of progress while the central clinical question remains unanswered. The next study must be judged on the actual effect, its consistency and its safety context, rather than whether management labels it positive.
Competition adds urgency. A more advanced exon 44 competitor could define expectations before Entrada reaches a pivotal trial. In DM1, September’s HARBOR failure shows why improvements in disease biology cannot be assumed to translate into a successful functional endpoint. VX-670 is mechanistically different, but still needs controlled clinical proof. Novartis update
The financial downside is progressive as well as event-driven. Additional cohorts, delays and eventual pivotal studies consume cash, while equity issuance spreads future value across more shares. Weak data could hurt both program value and financing terms. A major safety finding could also affect confidence across related programs, making the catalyst count look more diversified than the underlying risk really is.
As of September 27, Entrada is approaching the next patient readout with an unresolved translation problem. Its first DMD cohort showed biological activity and acceptable initial tolerability, but exposure was below expectations and the functional evidence came from a tiny exploratory dataset. The upcoming sequence can sharpen that picture. It cannot yet establish a broad clinical benefit or commercial franchise. May patient-data release · August clinical presentation
The competitive backdrop moved in September. Novartis is further along in exon 44, and its DM1 phase III failure reinforces the need to distinguish molecular correction from meaningful function. Investors therefore have to evaluate Entrada against a changing standard of evidence, not simply count announcements. September 8 Novartis filing
Entrada is a small clinical-stage company built around intracellular delivery. Its attraction is the combination of several pending datasets, a relatively small share base and owned DMD programs alongside a Vertex partnership. The company does not need every project to succeed for the information set to improve substantially. It does need a reproducible relationship between dose, exposure, molecular activity and patient outcomes.
The first ENTR-601-44 results leave room for both interpretations. Tolerability supports further study; lower-than-modeled exposure and limited functional evidence prevent a clean proof-of-concept verdict. ENTR-601-45 offers a second program test, and VX-670 tests delivery in a different disease. Shared technology still creates correlated risk. A successful readout would be informative without automatically validating every other molecule.
The financing position should allow several planned readouts under management’s assumptions. Continued trials nevertheless consume capital, and eventual pivotal development would require more resources. This hub separates disclosed facts, management schedules and analytical judgments. It assigns no target price or clinical success probability. Operating guidance · Financial statements and risks
Entrada named PPMD and Duchenne Parent Project Netherlands as recipients of two $50,000 grants. This is a patient-community initiative, not a clinical efficacy result.
HARBOR missed its primary DM1 endpoint, while del-zota had received priority review in exon 44 Duchenne. These developments affect the evidence bar and competitive timetable.
Entrada announced 61,365 RSUs and options over 19,425 shares for eight non-executive hires. The awards are subject to vesting, not an immediate issuance of the entire amount.
ENTR-601-45 cohort 1 is guided to October, ENTR-601-44 open-label follow-up to year-end and its higher-dose cohort to Q1 2027. These windows supersede earlier guidance.
18 detailed sections on Entrada Therapeutics, with financial statements, clinical evidence and regulatory documents identified by source and reference date.
Free access.
Entrada was incorporated in September 2016 as CycloPorters and adopted its current name in October 2017. Its public-market chapter began with the November 2021 IPO. It remains a development organization: clinical execution and financing discipline are more relevant today than commercial sales execution. IPO prospectus · 2026 proxy
Dipal Doshi has led the company since 2017 and previously served as chief business officer at Amicus. Executives include Natarajan Sethuraman, president of R&D; Nathan Dowden, president and chief operating officer; and CFO Kory Wentworth. Kush Parmar chairs the board separately from the CEO. Other directors include Peter Kim, Mary Thistle, Bernhardt Zeiher, Maha Radhakrishnan and Gina Chapman. Leadership biographies · Board and committees
Scientific, operating and investment experience can aid capital allocation, but it does not replace accountability. The classified board described in the proxy means shareholders do not elect all directors annually. The practical governance question is whether management updates dose selection, spending and priorities promptly when evidence changes. Venture representation can provide continuity while still requiring scrutiny of compensation and related-party disclosures.
Large therapeutic molecules can enter a cell yet remain trapped in compartments called endosomes. Entrada’s Endosomal Escape Vehicle, or EEV, uses a cyclic cell-penetrating peptide attached to therapeutic cargo to improve intracellular delivery and release. More useful drug reaching its target is the intended advantage. These are company-described design goals whose clinical value must be demonstrated. EEV platform description
In DMD, the cargo is a phosphorodiamidate morpholino oligomer, or PMO. Exon skipping aims to restore the RNA reading frame so cells produce a shorter dystrophin protein. Eligibility depends on mutation: an exon 44 candidate does not treat every person with Duchenne. This is repeat-dose treatment, not one-time gene replacement. Clinical-study overview
Delivery, target engagement and patient benefit are distinct hurdles. Exposure and exon skipping can support the mechanism; dystrophin moves closer to the disease biology; sustained function is what matters to patients. Success at one level does not establish the next. Claims about muscle stem-cell access and regenerative potential remain preclinical hypotheses, not established benefits in treated children.
| Program | Population | Current position | Economics |
|---|---|---|---|
| ENTR-601-44 | DMD exon 44 | Phase 1/2; higher dose and follow-up pending | Entrada-owned |
| ENTR-601-45 | DMD exon 45 | Phase 1/2; first patient data pending | Entrada-owned |
| ENTR-601-50 | DMD exon 50 | UK trial authorization; sequencing under review | Entrada-owned |
| ENTR-601-51 | DMD exon 51 | CTA-enabling work completed | Entrada-owned |
| VX-670 / former ENTR-701 | DM1 | Phase 1/2 GALILEO | Vertex-partnered |
| ENTR-801 | USH2A retinal disease | Preclinical | Entrada-owned |
Company pipeline · August update. Development stages are not approval probabilities. Discovery programs do not have established human efficacy.
The portfolio offers several experiments, but many share delivery chemistry, manufacturing requirements or biological assumptions. VX-670 has different disease biology and retained economics. Valuation should avoid treating everything as one binary bet or assigning each listed asset an independent, fully funded commercial value.
ELEVATE-44-201 started with eight ambulatory participants randomized 3:1 to treatment or placebo. Cohort 1 used 6 mg/kg intravenously every six weeks for three doses, with biopsy assessment at day 127. Actual ages were 6–17 within a 4–20 eligibility range. All eight entered open-label follow-up. May cohort report · August study slides
The reported dystrophin increase was 2.36 percentage points above a 4.00% baseline; exon skipping rose 2.31 points above 2.66%. These are absolute changes, not a 2.36-fold increase. There were no reported serious adverse events or adverse-event discontinuations, and described kidney markers remained normal. Pediatric exposure was below model predictions. A time-to-rise velocity finding reached p<0.05 in a post hoc analysis. Reported results
The February 2026 annual report had anticipated double-digit dystrophin in this first cohort; the reported result did not meet that earlier expectation. 2025 Form 10-K, filed February 26. Further dose investigation is justified, but this is not reliable proof of functional efficacy. Baseline dystrophin, patient heterogeneity, measurement variability and the tiny placebo group make superficial comparisons with other companies’ percentages misleading.
Cohort 2 increases dosing to 12 mg/kg, with results guided to Q1 2027; a later cohort could test up to 18 mg/kg. The question is whether greater exposure improves biological activity without narrowing the safety margin. Follow-up adds duration and repeat-dose information, but without a concurrent blinded comparator it cannot establish causality. A higher average driven by an outlier would be less persuasive than a coherent response across patients. Dose-escalation plan · Current timing
ELEVATE-45-201 studies ambulatory patients with exon 45-skipping amenable DMD. The phase 1/2 design plans 24 participants across three eight-person cohorts, randomized 3:1, with three intravenous doses six weeks apart before open-label treatment. Dose levels are 5 mg/kg, 10 mg/kg and potentially 15 mg/kg. Study and monitoring update
In June, the independent monitoring committee reviewed safety and pharmacokinetic information from the first eight participants and allowed escalation to 10 mg/kg. That is a development milestone, not a public efficacy demonstration. October is the next opportunity to examine patient results. Escalation decision · October guidance
A constructive result would connect tolerable dosing with adequate exposure and a credible molecular response. Weak findings would raise questions about whether ENTR-601-44’s challenges extend across the DMD platform. Neither outcome follows automatically, because cargo and populations differ. Functional observations remain exploratory until supported by appropriate size, duration and statistical design. Cohort 2 is guided to H1 2027 and cannot automatically be placed before March 31.
VX-670, formerly ENTR-701, is designed to address pathogenic CUG-repeat RNA in DM1 while preserving DMPK, unlike approaches that reduce DMPK RNA. GALILEO’s multiple-ascending-dose portion assesses safety, muscle-biopsy splicing correction and function, including video hand-opening time and quantitative muscle testing. Vertex expects data in H2 2026; no exact day is verified. Vertex Q2 update · DM1 overview
The December 2022 collaboration included $224 million upfront and $26 million in equity, paid at the 2023 closing, plus up to $485 million of contingent milestones and tiered royalties. Vertex handles global development, manufacturing and commercialization. Historical payments are not incoming catalyst cash; the milestone ceiling is not a receivable. Agreement economics · Closing confirmation
The readout has two implications: retained economic participation and evidence about delivery. They should not be double-counted. A successful medicine would not give Entrada all product revenue, while favorable delivery evidence still needs validation in each DMD candidate. The strongest result would align molecular correction with interpretable function rather than substitute the first for the second.
The sponsor’s trial page lists 47 participants for the overall GALILEO study and eligibility ages 18–64. This is not a claim that all 47 belong to the pending multiple-dose analysis. Exact dose-level allocation and numerical patient safety results are not established by the cited operating update and are left unspecified. Vertex trial page · NCT06185764 registry
ENTR-601-50 has UK authorization for a phase 1/2 trial; additional regulatory steps and timing are being evaluated against lead-program data. ENTR-601-51 has completed CTA-enabling studies, with filings similarly sequenced after review of ongoing work. Neither has a verified patient readout in this six-month window. Development update · Current pipeline
ENTR-801 targets USH2A exon 13 in inherited retinal disease. Proposed durability and intravitreal use remain preclinical development hypotheses. The anticipated nomination of another ocular candidate is a discovery milestone, not a clinical binary. Ocular presentation
These projects may become valuable if Entrada establishes transferable delivery capabilities. They also compete for finite money and attention. Delaying an asset until the lead programs clarify exposure and safety could reflect rational prioritization rather than scientific failure, although it reduces near-term announcements. An authorized trial, an initiated trial, a dosed patient and a clinical result are different stages and should be labeled accordingly.
| Window | Event | Decision-useful evidence |
|---|---|---|
| October 2026 | ELEVATE-45 cohort 1 | First patient exposure, safety and molecular response |
| H2 2026 | Vertex GALILEO / VX-670 | Splicing correction alongside function and tolerability |
| By year-end 2026 | ELEVATE-44 open-label follow-up | Duration, repeated-dose safety and consistency |
| Q1 2027 | ELEVATE-44 cohort 2, 12 mg/kg | Dose-response and safety margin at greater exposure |
Entrada guidance · Vertex guidance. These are reporting windows, not release dates. October and Q1 are distinct; the H2 and late-year events could cluster.
Guidance has already evolved. A conference appearance is not automatically new efficacy data, and “first half 2027” does not mean “first quarter.” No Entrada FDA action date is claimed. Recheck management’s latest communication before treating an event as imminent: slippage changes both the information available and the funding needed to reach the next milestone.
| Metric | Amount | Period |
|---|---|---|
| Cash, equivalents and securities | $223.005m | June 30, 2026 |
| Cash, equivalents and securities | $295.698m | December 31, 2025 |
| R&D expense | $35.369m | Q2 2026 |
| G&A expense | $10.492m | Q2 2026 |
| Collaboration revenue | $0.898m | Q2 2026 |
| Net loss | $42.763m | Q2 2026 |
| Operating cash used | $74.158m | H1 2026 |
Financial statements · Earnings release. Management expects funding into Q3 2027. No material funded borrowing is shown; operating-lease liabilities are $48.544 million.
R&D accounts for approximately 77% of the two major expense categories. Collaboration revenue is not recurring product sales and should not be projected as a stable commercial franchise. Historical first-half operating cash use annualizes to $148.3 million, but trial cadence, manufacturing, working capital and partner payments can change burn.
Practical financing runway ends before cash reaches zero: management needs time and negotiating flexibility. Cash supports experiments; it does not automatically fund all future pivotal development.
| Measure / date | USD million |
|---|---|
| Research and development | 35.369 |
| General and administrative | 10.492 |
| Measure / date | USD million |
|---|---|
| Dec 2025 | 295.698 |
| Mar 2026 | 254.900 |
| Jun 2026 | 223.005 |
Ordinary shares were 38,936,669 at July 31, 2026. June reporting includes 3,367,000 pre-funded warrants with a nominal $0.0001 exercise price, giving approximately 42.304 million basic economic shares. Potential awards comprise 6.768 million options, 2.880 million RSUs and 0.215 million PSUs. They are not all issued or immediately dilutive on the same basis. Capital-stock and award notes
A $150 million ATM agreement provides a financing mechanism; no shares were sold through it in Q2. Authorized shares, weighted-average EPS shares and outstanding shares are distinct. Choosing whichever denominator makes the stock look cheapest is unreliable.
Almost all the purchase price of pre-funded warrants has already been paid, so excluding them overstates the economic claim of an ordinary share. Options and awards require separate treatment for exercise price and vesting. September inducements also show why June’s award inventory is not a fixed ceiling. New award disclosure
Financing after good data can support progress on better terms, but still increases the denominator. The relevant question is how much capital the next plan requires per unit of uncertainty resolved, rather than simply whether shares remain below an arbitrary threshold.
| Disclosure | Verified amount | Snapshot |
|---|---|---|
| Baker Bros. 13F | 5,072,730 common shares | June 30; filed August 14, 2026 |
| MPM group 13D/A | 3,885,115 beneficial shares; approximately 9.98% | September 8 event; filed September 10 |
| CEO Form 4 | 8,724 mandatory tax sell-to-cover shares; 517,290 direct shares remained | September 2 transaction |
Baker primary filing · MPM primary filing · CEO Form 4. Cross-checks: institutional table and MPM filing mirror.
A 13F common-stock position differs from beneficial ownership including exercisable instruments. Affiliated MPM reporting persons must not be added as separate holders. These are snapshots, not proof of positions today.
MPM disclosed actual open-market reductions, but not the investment motive. The CEO sale covered mandatory taxes; calling it discretionary bearish selling would mislead. Institutional participation may aid liquidity and diligence without predicting outcomes or obliging a fund to remain invested. No unverified aggregate institutional-ownership percentage is asserted.
Novartis’s del-zota is a direct, more advanced exon 44 competitor: its accelerated-approval submission was reported in Q2 and priority review confirmed in September. Entrada needs a worthwhile clinical and treatment profile, not simply another exon-skipping molecule. Novartis Q2 update · September update
Sarepta’s casimersen is already marketed for exon 45. Sarepta’s applications seeking traditional-approval conversion for AMONDYS 45 and VYONDYS 53 have a February 28, 2027 FDA target date. ESSENCE missed its primary endpoint, despite numerical trends favoring treatment and subsequent post hoc analyses. The FDA decision is a competitor event, not a TRDA PDUFA, and may inform the broader evidentiary discussion. FDA-acceptance announcement
Novartis’s DM1 HARBOR trial missed its primary video hand-opening endpoint in September. Secondary and exploratory activity did not rescue that result. VX-670 differs mechanistically: importing the same outcome would be unjustified, but ignoring the warning about functional validation would be equally weak analysis. HARBOR disclosure
Compare assays, baseline dystrophin, age, disease stage, background care, biopsy timing and duration before drawing conclusions from separate studies. A headline percentage cannot establish superiority. Six-week dosing is attractive only if efficacy and safety persist across the interval.
The original U.S. ENTR-601-44 hold was lifted in February 2025. The separate adult ELEVATE-44-102 program remains subject to dose and design discussions; it is not the current global ambulatory study. Authorization permits investigation, not commercial approval. Hold-resolution filing · Adult-study update
The latest 10-Q describes licensed IP, including Ohio State-related rights, and states that Entrada has no issued patents covering its oligonucleotide therapeutic candidates. This does not mean the platform has no IP. Pending claims, licensed technology, know-how and regulatory exclusivity have different scopes and durations. No blanket expiry date or freedom-to-operate conclusion is assigned. IP risk disclosures
Scientific differentiation and enforceable commercial protection are separate questions. Good clinical data would leave manufacturing, regulatory, reimbursement and competitive issues. Accelerated approval is a possible route, not an FDA commitment to accept a particular biomarker dataset. Readers should avoid turning management’s development ambition into an assumed regulatory outcome.
The $6.16 September 25 close multiplied by July ordinary shares gives $239.85 million of equity value. Including pre-funded warrants gives $260.59 million. Subtracting June cash and securities produces approximately $37.59 million before leases, or $86.13 million after adding lease liabilities. Historical price · Price cross-check · Balance-sheet and share inputs
This mixed-date bridge is not live enterprise value: the cash predates the price by nearly three months and excludes subsequent spending. It is not liquidation analysis. Cash committed to development is consumed, leases remain obligations, and winding down costs money. Apparent proximity to cash does not create a trading floor.
A future model should separate owned DMD value from Vertex milestones and royalties, then deduct development costs and corporate expenses while allowing for financing. Eligible patients, uptake, pricing, competition, approval timing and probabilities must be explicit. Current data do not justify false precision. The useful exercise is sensitivity: identify which upcoming observations would change those assumptions, and in which direction. A low enterprise-value calculation is a starting point for those questions, not their answer.
Analyst coverage: the underlying dated brokerage notes have not been independently verified for this update, so this hub does not reproduce a target-price table or treat a vendor consensus as established fair value.
Reported September 15 short interest was 2,744,145 shares. MarketBeat reports 7.79% of its float estimate; Equibles reports 8.06 days to cover. The share count is corroborated, but float methods and volume windows differ. MarketBeat series · Equibles cross-check
This is meaningful positioning, not proof of an extreme squeeze. Days to cover can look high because ordinary volume is low; it does not mean every short must buy within that period. A favorable catalyst can attract demand and covering, while unfavorable data can overwhelm a small float with selling.
No verified aggregate Stocktwits bullish/bearish percentage is asserted. A live feed may show current discussion, but selected messages are not a representative investor survey. The useful questions are whether expectations have changed, liquidity can accommodate a position and discussion matches the trial design. Social enthusiasm and the short ratio cannot establish the probability or direction of a clinical surprise.
Constructive. Higher exposure produces reproducible molecular improvement with tolerable repeat dosing; ENTR-601-45 adds consistent evidence; follow-up supports the functional pattern; VX-670 contributes a clinically interpretable signal. This could improve development confidence and funding options. Outlier-dependent responses or an inadequate safety margin would weaken the scenario.
Intermediate. Safety is manageable but biomarkers and function remain mixed, variable or too imprecise to design a pivotal trial. More cohorts and observation are required. Programs retain plausibility while time, spending and competition erode option value. Clearly reproducible dose-response evidence or a definitive setback would move the assessment away from this middle case.
Adverse. Useful exposure is difficult to reach safely, functional observations fail to reproduce, timing slips or competition sets a stronger standard. Funding becomes harder precisely when more work is needed. A coherent controlled dataset would challenge this case; positive press-release adjectives alone would not.
These are analytical pathways, not probability-weighted forecasts. Multiple datasets can reduce uncertainty, but shared chemistry means several apparent catalysts can still depend on the same underlying problem.
Entrada’s next six months are unusually informative for a company of this size. The strongest reason to follow TRDA is the opportunity to see initial human activity become a repeatable clinical profile across doses and programs. The strongest caution is that the first dataset has not yet demonstrated that progression.
October’s exon 45 readout and Q1’s higher-dose exon 44 results occupy distinct windows, with DM1 and follow-up adding context. A useful update should strengthen the chain from exposure to molecular correction to patient function, while preserving safety and a credible funding plan. If that chain stays weak, the number of announcements and historical cash should not distract from it. This is a research framework, not a buy/sell instruction or promised return.
Research cut-off: September 27, 2026. Financial statements are primarily June 30; price is September 25; ownership and short-interest dates accompany the figures. Management expectations are not independently established outcomes. A release and its SEC reproduction verify transcription, not independent clinical replication.
Calculations and scenarios are this hub’s analysis. No unpublished results, release days, social-sentiment percentages, target prices or success probabilities have been invented. Current guidance supersedes earlier timing.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $TRDA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
